Status:
COMPLETED
Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils
Lead Sponsor:
Fudan University
Conditions:
Tumor Associated Neutrophils
Eligibility:
All Genders
Brief Summary
A single biomarker is not adequate to identify patients with colorectal cancer (CRC) who have the potential to benefit from adjuvant therapy, presumably owing to the complexity of tumor-infiltrating i...
Eligibility Criteria
Inclusion
- Voluntarily sign a written ICF.
- The Eastern Cancer Collaborative Organization (ECOG) has a physical fitness score of 0 or 1.
- The expected survival period is ≥ 3 months.
- 5\. Subjects diagnosed with metastatic colorectal adenocarcinoma by histology or cytology.
- 6\. Colorectal cancer patients who have not received systematic anti-tumor therapy in the past.
Exclusion
- Subjects suffered from other malignant tumors within 3 years before enrollment, except for cured local tumors (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, etc.).
- Simultaneously enroll in another clinical study, unless it is an observational, non-interference clinical study or a follow-up period of an intervention study.
- Received systematic anti-tumor therapy (chemotherapy) within 3 weeks prior to the first administration
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
653 Patients enrolled
Trial Details
Trial ID
NCT06495827
Start Date
July 1 2010
End Date
August 1 2023
Last Update
July 11 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.